Arrowhead Pharmaceuticals Aktie
62,10
EUR
-0,68
EUR
-1,08
%
71,82
USD
-0,11
USD
-0,15
%
Arrowhead Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Arrowhead Pharmaceuticals Aktie Analyse
| 07.09.18 | Arrowhead Pharmaceuticals Buy | B. Riley FBR | |
| 06.09.18 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
| 08.08.18 | Arrowhead Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 02.07.18 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
| 09.05.18 | Arrowhead Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 12.02.18 | Arrowhead Pharmaceuticals Neutral | Cantor Fitzgerald | |
| 12.02.18 | Arrowhead Pharmaceuticals Neutral | B. Riley FBR, Inc. | |
| 05.01.18 | Arrowhead Pharmaceuticals Neutral | B. Riley FBR, Inc. | |
|
Werbung
|
|||
| 30.11.16 | Arrowhead Pharmaceuticals Mkt Perform | William Blair | |
| 30.11.16 | Arrowhead Pharmaceuticals Hold | Cantor Fitzgerald | |
| 30.11.16 | Arrowhead Pharmaceuticals Neutral | Chardan Capital Markets | |
| 10.11.16 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
| 19.05.16 | Arrowhead Pharmaceuticals Buy | Chardan Capital Markets | |
| 09.10.14 | Arrowhead Pharmaceuticals Sector Perform | RBC Capital Markets | |
Werbung
Werbung